Indaptus Therapeutics (NASDAQ:INDP) Posts Earnings Results, Beats Expectations By $1.45 EPS

Indaptus Therapeutics (NASDAQ:INDP) posted its quarterly earnings results on Friday. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.46) by $1.45, Zacks reports.

Indaptus Therapeutics Price Performance

Shares of Indaptus Therapeutics stock traded up $0.03 during trading on Friday, hitting $3.18. 113,195 shares of the company’s stock traded hands, compared to its average volume of 588,813. Indaptus Therapeutics has a 1 year low of $0.92 and a 1 year high of $5.96. The stock has a market capitalization of $423.70 million, a P/E ratio of -0.50 and a beta of 0.96. The business has a 50-day simple moving average of $2.92 and a 200-day simple moving average of $2.31.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Indaptus Therapeutics currently has a consensus rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to stimulate the immune system to fight cancer and infectious diseases. Its approach uses proprietary bacterial-based candidates designed to activate multiple immune pathways. The company’s lead candidate, Decoy20, is an investigational immunotherapy made from a mixture of inactivated, non-pathogenic bacteria. Indaptus is evaluating the candidate in clinical research for advanced solid tumors; it has not been established as a treatment for any disease.